Evidence map›Paper›PMID 24577058›Full record

ArticleJournal of innate immunity2014

A new domain in the Toll/IL-1R domain-containing adaptor inducing interferon-β factor protein amino terminus is important for tumor necrosis factor-α receptor-associated factor 3 association, protein stabilization and interferon signaling.

Vinh-Phuc Nguyen, Jing Chen, Michael N Petrus, Carolyn K Goldman, Michael J Kruhlak, Richard N Bamford, Thomas A Waldmann

Open access · bronzeAbstract read
In one paragraph

Article in Journal of innate immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Role of TLRs as signaling cascades to combat infectious diseases: a review.Cellular and molecular life sciences : CMLS · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Vinh-Phuc NguyenMetabolism Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Md., USA.
Jing Chen
Michael N Petrus
Carolyn K Goldman
Michael J Kruhlak
Richard N Bamford
Thomas A Waldmann
Center for Cancer Research · USAptagen (United States) · USNational Institutes of Health · US

Funding

IL-2:IL-15 : implications for cancer therapy (Investigator -Initiated Project)ZIASC004002 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WALDMANN, THOMAS · 2009 to 2022
$22.9M
EIB Microscopy Core FacilityZICBC010915 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WISNIEWSKI, JAN · 2009 to 2025
$6.1M
Immunoregulatory Cell Receptor Defects--Leukemia/LymphomZ01SC004002 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI WALDMANN, THOMAS A · 1996 to 2008
$6.1M
Intramural NIH HHS Z01 SC004002
6 · The paper itself

Abstract

Toll/IL-1R domain-containing adaptor inducing interferon-β (IFN-β) factor (TRIF) is a key adaptor for Toll-like receptor (TLR) 3 and TLR4 signaling. Using a novel cDNA isolate encoding a TRIF protein with a 21-residue deletion (Δ160-181) from its amino-terminal half, we investigated the impact of this deletion on TRIF functions. Transfection studies consistently showed higher expression levels of the (Δ160-181) TRIF compared to wild-type (wt) TRIF, an effect unrelated to apoptosis, cell lines or plasmid amplification. Colocalization of wt and (Δ160-181) TRIF proteins led to a dramatic reduction of their respective expressions, suggesting that wt/(Δ160-181) TRIF heterocomplexes are targeted for degradation. We demonstrated that wt TRIF associates with tumor necrosis factor-α receptor-associated factor 3 (TRAF3) better than (Δ160-181) TRIF, culminating in its greater ubiquitination and proteolysis. This explains, in part, the differential expression levels of the two TRIF proteins. Despite higher expression levels in transfected cells, (Δ160-181) TRIF inefficiently transactivated the IFN pathway, whereas the nuclear factor-κB (NF-κB) pathway activation remained similar to that by wt TRIF. In coexpression studies, (Δ160-181) TRIF marginally contributed to the IFN pathway activation, but still enhanced NF-κB signaling with wt TRIF. Therefore, this 21 amino acid sequence is crucial for TRAF3 association, modulation of TRIF stability and activation of the IFN pathway.

Indexed as

Adaptor Proteins, Vesicular TransportHeLa CellsHumansInterferonsNF-kappa BProtein BindingProtein StabilityProtein Structure, TertiaryProtein TransportProteolysisSequence DeletionSignal TransductionTNF Receptor-Associated Factor 3Toll-Like Receptor 4Transcriptional ActivationAdaptor Proteins, Vesicular TransportInterferonsNF-kappa BTICAM1 protein, humanTNF Receptor-Associated Factor 3Toll-Like Receptor 4

Identifiers

PMID24577058
PMCPMC4058787
OpenAlexW1970179972

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.